Media coverage about AnaptysBio (NASDAQ:ANAB) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AnaptysBio earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.5102023229264 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
ANAB has been the topic of several recent research reports. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price objective on the stock in a research note on Friday, November 10th. JMP Securities boosted their price objective on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Wedbush reissued a “positive” rating and issued a $82.00 price objective (up from $75.00) on shares of AnaptysBio in a research note on Tuesday, November 7th. Credit Suisse Group boosted their price objective on shares of AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Finally, Royal Bank Of Canada initiated coverage on shares of AnaptysBio in a research note on Thursday, September 14th. They issued an “outperform” rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $84.78.
Shares of AnaptysBio (NASDAQ ANAB) traded down $1.05 during midday trading on Wednesday, hitting $78.18. 203,714 shares of the company’s stock traded hands, compared to its average volume of 206,831. AnaptysBio has a 52 week low of $15.17 and a 52 week high of $81.85. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.